Resources Repository
-
ReviewPublication 2016Decision Support for Infectious Disease Control
This report from RAND reviews decision-support tools, including models and nonmodeling approaches, that are relevant to …
This report from RAND reviews decision-support tools, including models and nonmodeling approaches, that are relevant to infectious disease prevention, detection, and response and aligns these tools with real-world policy questions that the tools can help address. This overview is designed to help modelers and other technical experts understand the questions that policymakers will raise and the decisions they must make. The report also presents policymakers with the capabilities and limitations of the different tools that may…
Dynamic Simulation | Dynamic Transmission | Mathematical Models | State-Transition | Microsimulation | Infectious Diseases | Global Governance | Government/Law | Health/Medicine | Military/Defense | Global -
GuidelinesPublication 2012Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Task Force-5
This paper reports the consensus-based guidelines on dynamic transmission modeling in health care. The transmissible …
This paper reports the consensus-based guidelines on dynamic transmission modeling in health care. The transmissible nature of communicable diseases is what sets them apart from other diseases modeled by health economists. The probability of a susceptible individual becoming infected at any one point in time (the force of infection) is related to the number of infectious individuals in the population, will change over time, and will feed back into the future force of infection. These…
Dynamic Simulation | Dynamic Transmission | Mathematical Models | Infectious Diseases | Health/Medicine -
GuidelinesPublication 2012Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Task Force-1
This paper provides an overview of the work of the joint Task Force between the …
This paper provides an overview of the work of the joint Task Force between the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), provides the overarching recommendations, and discusses future work that is needed. The audience for these papers includes anyone who build models, stakeholders who utilize their results, and those concerned with the use of models to support decision making. This article is part 1 of…
Dynamic Simulation | Dynamic Transmission | Costing Methods | Health Outcomes | Value of Information | Mathematical Models | State-Transition | Microsimulation | Calibration/Validation | Decision Analysis | Infectious Diseases | Health/Medicine -
ArticlePublication 2011Dynamic Policies for Controlling Spread of Emerging Infections
This paper illustrates the design and implementation of a dynamic health policy for the control …
This paper illustrates the design and implementation of a dynamic health policy for the control of a novel strain of influenza, where two types of interventions are assumed to be available during the epidemic: (1) vaccines and antiviral drugs, and (2) transmission reducing measures, such as social distancing or mask use, that may be turned "on" or "off" repeatedly during the course of epidemic. A modeling approach is described for developing dynamic health policies that allow…
Dynamic Simulation | Dynamic Transmission | Mathematical Models | Infectious Diseases | Health Systems | Policy/Regulation | Health/Medicine | Science/Technology | Global -
ArticlePublication 2009Cost Effectiveness Analysis of Including Boys in a HPV Vaccination Program in the U.S.
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a …
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a routine human papillomavirus (HPV) vaccination program for preadolescent girls. The analysis included girls and boys aged 12 years; interventions included HPV vaccination of girls alone and of girls and boys in the context of screening for cervical cancer. The authors found that with 75% vaccination coverage and an assumption of complete, lifelong vaccine efficacy, routine HPV vaccination of 12-year-old girls…
Cost-Effectiveness Analysis | Dynamic Transmission | Microsimulation | Calibration/Validation | Infectious Diseases | Chronic Disease/Risk | Clinical Care | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2008Health and Economic Implications of HPV Vaccination in the U.S.
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical …
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical carcinogenesis to compare the health and economic outcomes of vaccinating preadolescent girls in the US (at 12 years of age), and vaccinating older girls and women in catch-up programs (to 18, 21, or 26 years of age). The study also examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and…
Cost-Effectiveness Analysis | Dynamic Transmission | Microsimulation | Calibration/Validation | Infectious Diseases | Chronic Disease/Risk | Health Systems | Clinical Care | Economics/Finance | Health/Medicine | Science/Technology | North America -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
Resource PackPublication, Teaching Resource 2024Resource Pack: Extended Cost-Effectiveness Analysis
Health policies are intended to increase the uptake of effective and efficient interventions and result …
Health policies are intended to increase the uptake of effective and efficient interventions and result in health gains (e.g., premature mortality and morbidity averted). Health policies can also provide non-health benefits in addition to the sole well-being of populations and beyond the health sector. For instance, social and health insurance programs can prevent illness-related impoverishment and provide financial risk protection. Health policies can also improve the distribution of health in the population and promote health…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Costing Methods | Social Determinants | Health Systems | Policy/Regulation | Culture/Society | Economics/Finance | Health/Medicine | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ArticlePublication 2024Hypertension Care Cascades and Reducing Inequities in Cardiovascular Disease in LMIC
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries …
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries (LMICs) across wealth quintiles. Using individual-level data from nationally representative surveys in 44 LMICs, the researchers simulated improvements in the hypertension care cascade and assessed the distributional benefits. They raised diagnosis and treatment levels for all wealth quintiles to match the best-performing country quintile and estimated the resulting change in 10-year cardiovascular disease (CVD) risk. Results indicate greater health benefits…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine